Composition for promoting differentiation or proliferation of human adipose stem cells

Abstract

To provide a substance that effectively promotes differentiation of adipose-derived stem cells into adipocytes or proliferation of adipose-derived stem cells.SOLUTION: Provided is a composition for increasing skin elasticity and improving wrinkles, containing palmitamide as an active ingredient. The composition is a cosmetic composition, a food composition, a pharmaceutical composition, or a quasi-drug composition.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a method for treating psoriasis by the use of formononetin, emodin, artepillin C, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, niacin, niacinnamic acid ... The present invention relates to a cosmetic composition, food composition, pharmaceutical composition, quasi-drug composition, and composition for promoting the differentiation or proliferation of human adipose-derived stem cells for increasing skin elasticity and reducing wrinkles, each of which contains, as an active ingredient, one or more substances selected from the group consisting of riboflavin phosphate, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia extract, aloe extract, and fractions of the above extracts, and a method for increasing skin elasticity, which includes administering the composition to an individual other than a human. [Background technology]

[0002] Adipose tissue, along with muscle, supports the skin structure. While fat cells account for 30-40% of the total number of cells, they account for 90% of the total volume, making them crucial for skin structure. Subcutaneous adipose tissue decreases with aging, leading to a decrease in skin elasticity and increased wrinkles. Rapid weight loss often leads to a decrease in facial elasticity and increased wrinkles. Therefore, regulating the number of adipose tissue, which plays an important role in maintaining the skin's structure, and increasing its volume could potentially improve skin elasticity and wrinkles. However, fat transplantation, currently used to improve skin elasticity, has a very low in vivo survival rate for transplanted stem cells, necessitating reoperation after a certain period of time, and can lead to problems such as aggregation of transplanted fat. Therefore, research into materials that can strengthen the structure of the subcutaneous fat layer without surgery is essential.

[0003] However, conventional techniques for directly injecting adipose-derived stem cells can raise safety concerns, and techniques for mimicking components secreted during cell culture and delivering them to the skin have limitations, such as the difficulty of replicating actual components. Furthermore, as skin ages, human adipose-derived stem cells experience a decrease in cellular activity and a two-fold increase in proliferation time ( Gerontology 2011;57:66-75 (Non-Patent Document 1)). Therefore, adipose stem cells present in aging skin are significantly less responsive to other application techniques. Therefore, research is needed to identify substances that promote the proliferation of adipose stem cells and activate subcutaneous adipose tissue without causing skin irritation.

[0004] Furthermore, lips are the most dynamic part of the human body, constantly contracting and expanding. They are also constantly exposed to extreme environments, making them susceptible to environmental factors such as ultraviolet rays, cold, and dryness. Furthermore, lips differ in structure from normal skin and have a weaker defense mechanism. As lips age, they lose volume, wrinkle, and lose their attractive shape. In response, the development of a composition that provides excellent volume and wrinkle care for lips, just like normal skin, is essential. However, currently available technologies are limited to those that directly use wrinkle-reducing ingredients developed for facial skin or those that provide temporary volume enhancement. The latter volume enhancement phenomenon has a limitation, as it is due to an irritant reaction (Korean Patent Publication No. 10-2012-0140450 A (Patent Document 1)).

[0005] Recently, research into adipocyte or fat transplantation has focused on adipose-derived stem cells, which reside in subcutaneous adipose tissue and have the ability to differentiate into adipocytes. This is because adipokines secreted by adipose-derived stem cells are known to not only increase collagen synthesis in the dermis layer but also affect skin regeneration. Previously, substances known to differentiate preadipocytes into adipocytes were tested on mouse preadipocytes, and were less effective when applied to human adipose-derived stem cells. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Korean Patent Publication No. 10-2012-0140450 A [Non-patent literature]

[0007] [Non-Patent Document 1] Gerontology 2011;57:66-75 Summary of the Invention [Problem to be solved by the invention]

[0008] The inventors of the present invention have made extensive efforts to find a substance that effectively promotes the differentiation of adipose-derived stem cells into adipocytes or the proliferation of adipose-derived stem cells, and as a result have found that the following substances promote the differentiation process of human adipose-derived stem cells into adipocytes: formononetin, emodin, artepillin C, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, and sodium mannose phosphate. The present invention was completed based on the discovery that these substances can be used to increase skin elasticity and improve wrinkles. [Means for solving the problem]

[0009] One object of the present invention is to provide a method for the preparation of a skincare product containing formononetin, emodin, artepillin C, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, niacin, niacinnamic acid ... The present invention provides a cosmetic composition for improving skin elasticity and reducing wrinkles, which contains, as an active ingredient, one or more substances selected from the group consisting of riboflavin phosphate, lanosterol, riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia extract, aloe extract, and fractions of the above extracts.

[0010] Another object of the present invention is to provide a food composition for increasing skin elasticity and reducing wrinkles, which contains, as an active ingredient, one or more substances selected from the group consisting of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, Magnolia officinalis extract, aloe extract, fractions of Magnolia officinalis extract, and fractions of aloe extract.

[0011] Another object of the present invention is to provide a method for the preparation of a medicament for the treatment of rheumatoid arthritis, comprising administering to the patient a therapeutically effective amount of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, hydroxycinnamic ... The present invention provides a pharmaceutical composition for increasing skin elasticity and reducing wrinkles, which contains, as an active ingredient, one or more substances selected from the group consisting of hydroxybenzoates, ...

[0012] Another object of the present invention is to provide a method for the preparation of a medicament for the treatment of rheumatoid arthritis, comprising administering to the patient a therapeutically effective amount of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, hydroxycinnamic ... The present invention provides a quasi-drug composition for increasing skin elasticity and improving wrinkles, which contains, as an active ingredient, one or more substances selected from the group consisting of hydroxybenzoates, ...

[0013] Yet another object of the present invention is to provide a method for the preparation of a medicament for the treatment of rheumatoid arthritis, comprising administering to the patient a therapeutically effective amount of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, or the like. The present invention provides a composition for promoting differentiation of human adipose-derived stem cells, which contains, as an active ingredient, one or more substances selected from the group consisting of hydroxybenzoates, ...

[0014] It is yet another object of the present invention to provide a method for increasing skin elasticity, which comprises administering the above composition to a non-human individual. [Effects of the Invention]

[0015] The composition of the present invention is used for anti-aging purposes by promoting the differentiation of human adipose-derived stem cells into adipocytes and promoting the proliferation of human adipose-derived stem cells, thereby strengthening the structure of the subcutaneous fat layer, increasing skin elasticity, and improving wrinkles. [Brief explanation of the drawings]

[0016] [Figure 1] This shows the results of staining differentiated intracellular lipids with Oil Red O after treating human adipose-derived stem cells with formononetin, acetylmandelic acid, and Magnolia officinalis extract. [Figure 2]Quantitatively shows the relative differentiation rates of human adipose-derived stem cells treated with formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, Magnolia officinalis extract, and aloe extract. [Figure 3] 1 shows the results of comparing the number of people whose wrinkles at the corners of the eyes and lips were improved by using Magnolia extract. [Figure 4a] This shows that the improvement in lip wrinkles was sustained up to 12 weeks after treatment with Magnolia officinalis extract in subject 1. [Figure 4b] This shows that the improvement in lip wrinkles was sustained up to 12 weeks after treatment with Magnolia officinalis extract in subject 2. [Figure 5] 1 shows the results of a comparison of the improvement rates of wrinkles around the eyes and lips between Magnolia officinalis extract and asiaticoside, a conventional wrinkle improvement material. [Figure 6] The figure shows the cell activity rate of human adipose-derived stem cells treated with raspberry ketone, gallic acid, caffeic acid, carnosic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, xanthophyll, onion, bran, bamboo, carrot, and hibiscus extract. DETAILED DESCRIPTION OF THE INVENTION

[0017] This will be explained in more detail as follows. Meanwhile, each description and embodiment disclosed in this application may also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the specific description given below is not intended to limit the scope of this application.

[0018] In one embodiment of the present invention, a composition containing formononetin, emodin, artepillin C, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, niacin, niacinnamic acid ... Provided is a cosmetic composition for increasing skin elasticity and reducing wrinkles, comprising one or more active ingredients selected from the group consisting of riboflavin phosphate, lanosterol, riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia extract, aloe extract, and fractions of the above extracts. The composition may contain one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen of the above active ingredients.

[0019] In another embodiment of the present invention, there is provided a cosmetic composition for increasing skin elasticity and reducing wrinkles, comprising as an active ingredient formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menadione, thioctic acid, lactoflavin, or a cosmetically acceptable salt of xanthophyll.

[0020] In the present invention, the term "cosmetically acceptable salt" refers to, but is not limited to, a salt form in which formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, or xanthophyll is combined with another substance, and which exhibits cosmetic activity similar to that of the above-mentioned compounds.

[0021] The inventors of the present invention have made extensive efforts to develop a substance that can activate and restore the aged subcutaneous fat layer, and as a result have discovered formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, and the like. We have developed substances that promote the differentiation of human adipose-derived stem cells into adipocytes and the proliferation of human adipose-derived stem cells, including hydroxybenzoates (hydroxybenzoates), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia extract, and aloe extract. Through this, we have found that compositions containing these substances can be used as cosmetic compositions for increasing skin elasticity and improving wrinkles. The effects of these substances on increasing skin elasticity and improving wrinkles have never been reported before, and the fact that they were first discovered by the inventors is of great significance.

[0022] The molecular formula of the term "formononetin" in the present invention is C 16 H 12 O4, has a molecular weight of 284.26, and can be represented by the following chemical formula (1).

[0023] [ka]

[0024] The formononetin of the present invention can be isolated from plants including licorice, but is not limited to a method for obtaining it, and can be chemically synthesized by methods known in the art or commercially available substances can be used.

[0025] The molecular formula of the term "Emodin" in the present invention is C 15 H 10 O5, has a molecular weight of 270.24, and can be represented by the following chemical formula (2).

[0026] [ka]

[0027] The emodin of the present invention is not limited by the method for obtaining it, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0028] The molecular formula of the term "artepillin C" in the present invention is C 19 H 24 O3, has a molecular weight of 300.40, and can be represented by the following chemical formula (3).

[0029] [ka]

[0030] The artepillin C of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0031] The molecular formula of the term "carnosic acid" in the present invention is C 20 H 28 O4, has a molecular weight of 332.44, and can be represented by the following chemical formula (4).

[0032] [ka]

[0033] The method for obtaining the carnosic acid of the present invention is not limited, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0034] The term "palmitamide" as used herein refers to a normal chain fatty acid amide having 16 carbon atoms and the molecular formula is C 16 H 33 NO has a molecular weight of 255 and can be represented by the following chemical formula (5).

[0035] [ka]

[0036] The palmitamide of the present invention is not limited by its method of acquisition, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0037] The molecular formula of the term "Sodium Guaiazulene Sulfonate" in the present invention is C 15 H 17 It is NaO3S, has a molecular weight of 300.35, and can be represented by the following chemical formula (6).

[0038] [ka]

[0039] The sodium guaiazulene sulfonate of the present invention is not limited to a method for obtaining it, and may be chemically synthesized by a method known in the art, or may be a commercially available substance.

[0040] The molecular formula of the term "caffeic acid" in the present invention is C9H8O4, the molecular weight is 180.157, and it can be represented by the following chemical formula (7).

[0041] [ka]

[0042] The caffeic acid of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0043] The term "acetyl mandelic acid" of the present invention may specifically refer to "O-acetyl mandelic acid", whose molecular formula is C 10 H 10 O4, has a molecular weight of 194.186, and can be represented by the following chemical formula (8).

[0044] [ka]

[0045] The acetylmandelic acid of the present invention is not limited by the method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0046] The term "laccaic acid" as used herein refers to a natural anthraquinone, a dark red crystal produced by coagulating the secretions of the lac insect (Laccifer lacca Kerr), and is known to be primarily used as a dye. The laccaic acid may be, but is not limited to, laccaic acid A, B, C, D, E, or F. In one embodiment of the present invention, Sigma-Aldrich 50506 (Natural Red 25) was used as the laccaic acid.

[0047] The laccaic acid of the present invention is not limited by the method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0048] The term "ubiquinone" as used herein refers to a fat-soluble quinone, which is a component of the mitochondrial electron transport system. Specifically, the ubiquinone may be, but is not limited to, ubiquinone (10), whose molecular formula is C 59 H 90 O4, molecular weight is 863.37, and can be represented by the following chemical formula (9).

[0049] [ka]

[0050] The ubiquinone of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0051] The molecular formula of the term "hydroxycinnamic acid" used in the present invention is C9H8O3, with a molecular weight of 164.158, and may include isomers based on the position of the -OH group directly substituted on the benzene ring (o-, m-, p-hydroxycinnamic acid) and isomers based on the double bond (cis-coumarinic acid and trans-coumaric acid), specifically, m-coumaric acid, but is not limited thereto. The hydroxycinnamic acid can be represented by the following chemical formula (10):

[0052] [ka]

[0053] The hydroxycinnamic acid of the present invention is not limited to a method for obtaining it, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0054] The term "xanthophyll" as used herein refers to a carotenoid oxycarotenoid pigment present in the green parts of plants such as leaves, flowers, and fruits, which has a yellow color and has the molecular formula C 40 H 56 O2 and has a molecular weight of 569. Specifically, the xanthophyll may be lutein, which can be represented by the following chemical formula (11).

[0055] [ka]

[0056] The xanthophyll or lutein of the present invention is not limited to a method for obtaining it, and may be chemically synthesized by a method known in the art, or may be a commercially available substance.

[0057] The molecular formula of the term "raspberry ketone" used in the present invention is C 10 H 12 O2, has a molecular weight of 164.20, and can be represented by the following chemical formula (12).

[0058] [ka]

[0059] The raspberry ketone of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0060] The molecular formula of the term "gallic acid" in the present invention is C7H6O5, the molecular weight is 170.12, and it can be represented by the following chemical formula (13).

[0061] [ka]

[0062] The gallic acid of the present invention is not limited by the method of obtaining it, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0063] The molecular formula of the term "terpineol" in the present invention is C 10 H 18 O, the molecular weight is 154, and it can be represented by the following chemical formula (14).

[0064] [ka]

[0065] The terpineol of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0066] The molecular formula of the term "sodium mannose phosphate" used in the present invention is CH 12 O9PNA, molecular weight 282.12. Specifically, the sodium mannose phosphate may be, but is not limited to, sodium mannose 6-phosphate or D-mannose-6-phosphate sodium salt, which can be represented by the following chemical formula (15):

[0067] [ka]

[0068] The sodium mannose phosphate of the present invention is not limited to a method for obtaining it, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0069] The molecular formula of the term "tropolone" of the present invention is C7H6O2, the molecular weight is 122, and it can be represented by the following chemical formula (16).

[0070] [ka]

[0071] The tropolone of the present invention is not limited by the method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0072] The molecular formula of the term "glycyrrhetinic acid" in the present invention is C 30 H 46 O4, has a molecular weight of 471, and can be represented by the following chemical formula (17).

[0073] [ka]

[0074] The glycyrrhetinic acid of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0075] The molecular formula of the term "lanosterol" in the present invention is C 30 H 50 O, the molecular weight is 427, and it can be represented by the following chemical formula (18).

[0076] [ka]

[0077] The lanosterol of the present invention is not limited to a method for obtaining it, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0078] The molecular formula of the term "sodium riboflavin phosphate" in the present invention is C 17 H 20It is N4NaO9P, has a molecular weight of 478.33, and can be represented by the following chemical formula (19).

[0079] [ka]

[0080] The method for obtaining the riboflavin sodium phosphate of the present invention is not limited, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0081] The term "menadione" as used herein refers to a yellow crystal of vitamin K, with the molecular formula C 11 It is H8O2, has a molecular weight of 172.18, and can be represented by the following chemical formula (20).

[0082] [ka]

[0083] The menadione of the present invention is not limited by the method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0084] The term "thioctic acid" as used herein is also known as lipoic acid, and its molecular formula is CH 14 It is O2S2, has a molecular weight of 206, and can be represented by the following chemical formula (21).

[0085] [ka]

[0086] The thioctic acid or lipoic acid of the present invention is not limited to a method for obtaining it, and it can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0087] The term "lactoflavin" as used herein means riboflavin (vitamin B2) isolated from milk. The molecular formula of lactoflavin of the present invention is C 17 H 20 It is N4O6, has a molecular weight of 376.36, and can be represented by the following chemical formula (22).

[0088] [ka]

[0089] The lactoflavin of the present invention is not limited to a method for obtaining it, and can be chemically synthesized by a method known in the art, or a commercially available substance can be used.

[0090] The formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, or xanthophyll may exist in a solvated or unsolvated form. The compounds may also exist in a crystalline or amorphous form, and all such physical forms are within the scope of the present invention.

[0091] It is also obvious that the scope of the above compounds includes not only the above compounds but also cosmetically, food-wise and pharmaceutically acceptable salts thereof.

[0092] The term "onion (Allium cepa)" as used herein refers to a monocotyledonous biennial plant of the family Liliaceae, which contains quercetin, chromium, and allicin as major components and is known to have anti-inflammatory, blood sugar regulating, and blood pressure lowering effects. Onions may be purchased commercially, or may be collected or cultivated from the wild, and roots, stems, leaves, etc. may be used without limitation.

[0093] The term "rice bran" as used herein refers to a ground mixture of pericarp, seed coat, aleurone layer, etc., which is produced when brown rice is polished to produce polished rice. Rice bran contains minerals such as vitamins B1, B2, and niacin, as well as oryzanol, tocopherol, and phytic acid, and is known to have effects such as lowering blood cholesterol, antioxidant properties, and anticancer properties.

[0094] The term "bamboo (Bambusoideae)" as used herein refers to a monocotyledonous evergreen perennial plant belonging to the subfamily Bambusoideae of the family Poaceae in the order Poaceae, and is known in traditional Korean medicine for its antioxidant, antibacterial, and anticancer effects. Bamboo may be purchased commercially, collected from the wild, or cultivated, and its roots, stems, leaves, etc. may be used without limitation.

[0095] The term "carrot (Daucus carota var. sativa)" as used herein refers to a dicotyledonous biennial plant of the Umbelliferae family, which contains beta-carotene and lycopene as major components and is known to have antioxidant, anti-aging, and immune-boosting effects. The carrot may be purchased commercially, collected from nature, or cultivated, and its roots, stems, leaves, etc. may be used without limitation.

[0096] The term "hibiscus (Rose of China, Hibiscus)" as used herein refers to a dicotyledonous plant belonging to the genus Hibiscus, family Malvaceae, order Malvaceae, which is rich in hibiscus acid, hydroxycitric acid, etc. and is known to be effective in preventing obesity, etc. The hibiscus may be purchased commercially, collected from nature, or cultivated, and its roots, stems, leaves, etc. may be used without limitation.

[0097] The term "magnolia cortex" as used herein refers to the dried stem and root bark of the magnolia tree, a plant of the Magnoliaceae family, and contains lignans and essential oil components as its main active ingredients. Magnolia cortex is known to have anti-inflammatory, analgesic, smooth muscle regulating, and anti-ulcer effects. Magnolia cortex can be purchased commercially, or collected or cultivated in the wild, without any restrictions.

[0098] The term "aloe vera" as used herein refers to a perennial plant belonging to the genus Aloe in the family Liliaceae, also known as lokai. It contains aloin, aloe-emodin, aloetin, aromycin, etc. as its main active ingredients, and is known to have antibacterial, antifungal, antitumor, and other effects. The aloe may be purchased commercially, or collected or cultivated from nature, and can be used without restriction.

[0099] The term "extract" as used herein refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it for a certain period of time at room temperature, low temperature, or elevated temperature, or a solid component obtained by removing the solvent from the liquid component. It can also be comprehensively interpreted to include not only the above-mentioned product, but also dilutions of the above-mentioned product, concentrates thereof, and crude and purified products thereof.

[0100] In the present invention, the extract may be an extract of onion, bran, bamboo, carrot, hibiscus, magnolia, or aloe. The extract may be extracted from various organs of natural, hybrid, or variant plants, such as roots, aboveground parts, stems, leaves, flowers, fruit bodies, and fruit skins, as well as plant tissues. The extract may be obtained by extraction with water or various organic solvents. The organic solvent used is not particularly limited as long as it can produce an extract. Specifically, the organic solvent may be water, a polar solvent, or a nonpolar solvent. More specifically, the organic solvent may be water, a lower alcohol having 1 to 6 carbon atoms (e.g., methanol, ethanol, propanol, or butanol), a polyhydric alcohol such as glycerin or butylene glycol, a hydrocarbon solvent such as methyl acetate or ethyl acetate, or a mixture thereof. More specifically, the organic solvent may be water, a lower alcohol, 1,3-butylene glycol, or a mixture thereof.

[0101] Furthermore, the method for obtaining the extract is not particularly limited as long as it can obtain the onion, rice bran, bamboo, carrot, hibiscus, magnolia, or aloe extract. Specifically, methods that can be used include a cold immersion extraction method in which the roots, stems, leaves, fruits, flowers, dried products, or processed products of the magnolia or aloe are immersed in the solvent and extracted at room temperature; a heated extraction method; an ultrasonic extraction method in which extraction is performed by applying ultrasonic waves; and a reflux extraction method using a reflux condenser.

[0102] The term "fraction" as used herein refers to a product obtained by fractionating a mixture containing a variety of components to separate a specific component or a specific group of components. In the present invention, the fraction may be a fraction of onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia extract, or aloe extract.

[0103] In the present invention, the fractionation method for obtaining the fractions is not particularly limited as long as it can achieve the effects of increasing skin elasticity and reducing wrinkles, and may be a method commonly used in the art, such as solvent fractionation using various solvents, ultrafiltration fractionation using ultrafiltration membranes with a specific molecular weight cut-off value, chromatographic fractionation using various chromatographies (designed for separation by size, charge, hydrophobicity, or affinity), or a combination thereof.

[0104] In the present invention, the type of fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fractionation solvent include polar solvents such as water, distilled water, and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These solvents can be used alone or in combination. When alcohol is used as the fractionation solvent, C1 to C4 alcohols can be used.

[0105] The cosmetic composition of the present invention contains formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid The composition may contain one or more substances selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl cellulose (hydroxypropyl cellulose), lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia extract, aloe extract, fractionated Magnolia extract, and fractionated aloe extract in an amount of 0.0001 to 10% by weight (w / w) based on the total weight of the composition, specifically, but not limited to, 0.0005 to 10% by weight (w / w), 0.001 to 5% by weight (w / w), or 0.0001 to 2% by weight (w / w). If the amount is less than 0.0001% by weight, the effect may be minimal, and if it is 2% by weight or more, cytotoxicity may occur.

[0106] In the present invention, the cosmetic composition can promote the differentiation of human adipose-derived stem cells into adipocytes or the proliferation of human adipose-derived stem cells. That is, the cosmetic composition may promote the differentiation of human adipose-derived stem cells into adipocytes or the proliferation of human adipose-derived stem cells, thereby increasing skin elasticity and improving wrinkles.

[0107] The term "human adipose-derived stem cells" as used herein refers to stem cells that can be extracted from human adipose tissue and are multipotent cells that can differentiate into a variety of body cells. Adipose-derived stem cells are present in subcutaneous adipose tissue and have the ability to differentiate into adipocytes. Adipokines secreted by adipose-derived stem cells are known to not only increase collagen synthesis in the dermis layer of the skin, but also affect skin regeneration.

[0108] The term "adipose cell" as used herein means a cell that stores fat in the adipose tissue of an individual, and specifically may refer to, but is not limited to, white adipocytes present in the subcutaneous fat layer.

[0109] In one embodiment of the present invention, human adipose-derived stem cells were treated with formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, Magnolia officinalis extract, and aloe extract, and it was confirmed that the differentiation of human adipose-derived stem cells into adipocytes could be effectively promoted. Therefore, the composition of the present invention containing the above substances can be used for anti-aging purposes by increasing skin elasticity and improving wrinkles.

[0110] In one embodiment of the present invention, human adipose-derived stem cells were treated with raspberry ketone, gallic acid, caffeic acid, carnosic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, xanthophyll, onion, bran, bamboo, carrot, and hibiscus extract, and the results showed a significant increase in cell activity and promotion of proliferation of the human adipose-derived stem cells compared to the control group. Therefore, the composition of the present invention containing the above substances can be used for anti-aging purposes by increasing skin elasticity and improving wrinkles.

[0111] The term "increasing skin elasticity" as used herein means enhancing the elasticity of the skin by strengthening the structure of the subcutaneous fat layer of an individual using the composition of the present invention. The skin may be located anywhere on the individual's skin, as long as the composition of the present invention can improve elasticity and wrinkles.

[0112] The term "improvement" as used herein means that the symptoms of skin wrinkles in an individual are alleviated using the composition of the present invention.

[0113] One aspect of the present invention provides a cosmetic composition for increasing lip skin elasticity and reducing wrinkles, comprising, as an active ingredient, one or more substances selected from the group consisting of formononetin, emodin, artepillin C, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, Magnolia officinalis extract, aloe extract, a fraction of Magnolia officinalis extract, and a fraction of aloe extract.

[0114] One embodiment of the present invention may be a cosmetic composition for increasing lip skin elasticity and reducing wrinkles, comprising one or more substances selected from the group consisting of Magnolia officinalis extract and fractions of Magnolia officinalis extract.

[0115] Unlike other areas of the skin, lips lack sebaceous glands and have a very thin stratum corneum. Currently, most lip volume and wrinkle-reducing ingredients are used to improve the dermis layer, limiting their widespread application. Furthermore, because the stratum corneum of the lips is very thin, active ingredients penetrate and deliver more easily than those of other areas of the skin. Therefore, techniques for improving the volume of the subcutaneous fat layer are expected to be more effective in terms of improving volume and wrinkles. The composition of the present invention is characterized by its excellent effectiveness on such lip skin. In one embodiment of the present invention, Magnolia officinalis extract was found to be highly effective in improving wrinkles on both the corners of the eyes and lips, with a higher improvement rate and improvement rate on the lips than on the corners of the eyes.

[0116] The cosmetic composition for lips and skin may be prepared in a dosage form selected from the group consisting of lipstick, lip gloss, lip tint, and lip balm, but is not limited thereto.

[0117] In the present invention, the cosmetic composition may be prepared in a dosage form selected from the group consisting of a solution, an ointment for external use, a cream, a foam, a nutritious lotion, a softening lotion, a pack, a softening lotion, a milky lotion, a makeup base, an essence, a soap, a liquid cleanser, a bath additive, a sunscreen cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray, but is not limited thereto.

[0118] Furthermore, the cosmetic composition of the present invention may further contain one or more cosmetically acceptable carriers that are commonly incorporated into skin cosmetics, and may contain, as appropriate, common ingredients such as oils, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, and fragrances, but is not limited to these.

[0119] The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the formulation.

[0120] When the dosage form of the present invention is an ointment, paste, cream or gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, bentonite, silica, talc, zinc oxide or a mixture thereof.

[0121] When the dosage form of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or mixtures thereof may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be further included.

[0122] When the dosage form of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, and in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycol or fatty acid esters of sorbitan.

[0123] When the dosage form of the present invention is a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth.

[0124] When the dosage form of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydroxylates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils and fats, glycerol, sugars, etc. may be used as carrier components.

[0125] The cosmetic composition of the present invention contains formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid In addition to one or more substances selected from the group consisting of hydroxypropyl hydroxypropyl methylcellulose, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia extract, aloe extract, and fractions of the above extracts, the composition may contain commonly used adjuvants such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blocking agents, pigments, odor absorbers, and dyes.

[0126] Another aspect of the present invention is a composition comprising a sucralose, ... The present invention provides a food composition for increasing skin elasticity and reducing wrinkles, comprising one or more active ingredients selected from the group consisting of hydroxybenzoates, ...

[0127] The formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia sinensis, aloe vera extract, extracts, fractions, and skin elasticity enhancement and improvement are as described above.

[0128] The present invention also provides a food composition for increasing skin elasticity and reducing wrinkles, comprising as an active ingredient formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menadione, thioctic acid, lactoflavin, or a nutritively acceptable salt of xanthophyll.

[0129] In the present invention, the term "food-based acceptable salt" refers to a salt form in which formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menadione, thioctic acid, lactoflavin, or xanthophyll is bound to another substance, and which exhibits food-based activity similar to that of the above-mentioned compounds.

[0130] The food composition of the present invention contains formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid In addition to one or more substances selected from the group consisting of hydroxypropyl cellulose, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia extract, aloe extract, and fractions of the above extracts, the composition may contain other food-safe and / or dietary-acceptable food supplement additives.

[0131] In the present invention, the term "supplementary food additive" refers to a component that can be added supplementarily to food, and is added to produce various forms of functional health foods, and can be appropriately selected and used by those skilled in the art. Examples of supplementary food additives include, but are not limited to, various nutrients, vitamins, minerals (electrolytes), flavorings such as synthetic flavorings and natural flavorings, coloring agents and fillers, pectinic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonation agents used in carbonated beverages.

[0132] The functional food composition of the present invention may include a functional health food. In the present invention, the term "functional health food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., using raw materials or ingredients that have beneficial functions for the human body. Here, "functional" refers to obtaining beneficial effects for health purposes, such as regulating nutrients for the structure and function of the human body or achieving physiological effects. The functional health food of the present invention may be prepared by methods commonly used in the art, and may be prepared by adding raw materials and ingredients commonly added in the art. Furthermore, the dosage form of the functional health food may be prepared without limitation, as long as it is recognized as a functional health food. The food composition of the present invention may be prepared in various dosage forms. Unlike common pharmaceuticals, the functional health food of the present invention has the advantage of being made from food ingredients, eliminating side effects that can occur with long-term drug administration, and is highly portable. The functional health food of the present invention can be taken as an adjunct for increasing skin elasticity and reducing wrinkles.

[0133] The functional health food of the present invention may take any form, including any food in the conventional sense, and may be interchangeably referred to as functional food or other terms known in the art. The functional health food of the present invention may also be prepared by mixing other appropriate supplementary ingredients and known additives that may be included in food, as selected by those skilled in the art. Examples of foods to which the functional health food of the present invention may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinking water, tea, health supplements, alcoholic beverages, and vitamin complexes. Foods used as animal feed are also included.

[0134] Another aspect of the present invention is a composition comprising a sucralose, ... The present invention provides a pharmaceutical composition for increasing skin elasticity and reducing wrinkles, comprising one or more active ingredients selected from the group consisting of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, Magnolia officinalis, aloe extract, extracts, fractions thereof, and the increase and improvement of skin elasticity.

[0135] The present invention also provides a pharmaceutical composition for increasing skin elasticity and reducing wrinkles, comprising as an active ingredient a pharmaceutically acceptable salt of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, or xanthophyll.

[0136] In the present invention, the term "pharmaceutically acceptable salt" refers to a salt form in which formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menadione, thioctic acid, lactoflavin, or xanthophyll is combined with another substance, and which exhibits pharmacological activity similar to that of the above-mentioned compounds.

[0137] The pharmaceutical composition of the present invention may be used as a single preparation, or may be prepared as a combined preparation by further including a drug known to have the effects of increasing skin elasticity and improving wrinkles. By formulating the composition using a pharmaceutically acceptable carrier or excipient, the composition may be prepared in the form of a unit dose or may be prepared in a multi-dose container.

[0138] The pharmaceutical composition can be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment, and the effective dose level can be determined based on factors including the type and severity of the individual, age, sex, drug activity, drug sensitivity, administration time, administration route and excretion rate, treatment duration, concurrently used drugs, and other factors well known in the medical field.

[0139] Another aspect of the present invention provides a quasi-drug composition for increasing skin elasticity and reducing wrinkles, comprising one or more active ingredients selected from the group consisting of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia extract, aloe extract, and fractions of the above extracts. In this invention, the composition can increase skin elasticity and reduce wrinkles by promoting the differentiation of human adipose-derived stem cells into adipocytes. The formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion, bran, bamboo, carrot, hibiscus, magnolia, aloe, extract, fraction, and skin elasticity increase and improvement are as described above.

[0140] The present invention also provides a quasi-drug composition for increasing skin elasticity and reducing wrinkles, comprising as an active ingredient a pharmaceutically acceptable salt of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menadione, thioctic acid, lactoflavin, or xanthophyll. The "pharmaceutically acceptable salt" is as defined above.

[0141] The quasi-drug composition of the present invention may further contain, as necessary, a pharmaceutically acceptable carrier, excipient, or diluent in addition to the above-mentioned components. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effects of the present invention, and may include, for example, a filler, extender, binder, wetting agent, disintegrant, surfactant, lubricant, sweetener, flavoring agent, preservative, etc.

[0142] The term "pharmaceutically acceptable carrier" refers to a carrier, excipient, or diluent that does not stimulate the organism but does not inhibit the biological activity and properties of the compound being injected. Specifically, it may be a non-natural carrier. The type of carrier that can be used in the present invention is not particularly limited, and any pharmaceutically acceptable carrier commonly used in the art may be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, etc. These may be used alone or in combination.

[0143] The above-mentioned compositions containing pharmaceutically acceptable carriers may be in various oral or parenteral dosage forms. When formulated, they are prepared using commonly used diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Specifically, solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like. These solid formulations may be prepared by mixing the above-mentioned compounds with at least one or more excipients, such as starch, calcium carbonate, sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Oral liquid formulations include suspensions, oral solutions, emulsions, syrups, and the like. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, may also be used. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, twin 61, cocoa butter, laurin butter, and glycerogelatin.

[0144] Examples of the quasi-drug composition of the present invention include disinfectants, shower foams, ointments, wet tissues, and coating agents, but are not limited to these. The formulation method, dosage, method of use, constituents, and the like of the quasi-drug can be appropriately selected from conventional techniques known in the technical field.

[0145] The quasi-drug composition of the present invention can also be used in a method for improving skin wrinkles, which includes applying the composition to the skin of an individual. The individual includes, without limitation, mammals, including rats, livestock, and humans.

[0146]

[0013] In yet another aspect of the present invention, there is provided a composition for promoting differentiation of human adipose-derived stem cells, comprising one or more active ingredients selected from the group consisting of formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, Magnolia officinalis extract, aloe extract, a fraction of Magnolia officinalis extract, and a fraction of aloe extract.

[0014] In this invention, the composition promotes differentiation of human adipose-derived stem cells into adipocytes, thereby increasing skin elasticity and reducing wrinkles. The formononetin, emodin, artepillin, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion, bran, bamboo, carrot, hibiscus, magnolia, aloe, extract, fraction, and skin elasticity increase and improvement are as described above.

[0147] Yet another aspect of the present invention provides a method for increasing skin elasticity, comprising administering the above-described composition to a non-human individual.

[0148] The term "administration" as used herein means introducing the composition of the present invention into a patient by any suitable method, and the administration route of the composition can be any common route as long as it can reach the target tissue. Examples of administration include, but are not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, and intranasal administration. Because the composition of the present invention is effective in improving skin elasticity and reducing wrinkles, the composition can be administered by applying it to the skin.

[0149] The composition of the present invention may be administered daily or intermittently, and may be administered once or in 2-3 divided doses per day. The composition of the present invention may be administered alone or in combination with other drug treatments to improve skin elasticity and reduce wrinkles. Taking all of the above factors into consideration, it is important to administer an amount that provides maximum efficacy with the minimum amount without side effects, and this can be easily determined by those skilled in the art.

[0150] The term "individual" as used herein refers to any animal, including humans, such as rats, mice, livestock, and the like, that has or may develop reduced skin elasticity or wrinkles. Specifically, it may be any mammal, including humans.

[0151] The present invention will be described in more detail below with reference to the following examples, which are merely for illustrative purposes and are not intended to limit the scope of the present invention.

[0152] Example 1: Preparation of Magnolia and Aloe Extracts

[0153] The Magnolia cortex extract in this example was purchased from Borac Co., Ltd. (Hwaseong, Gyeonggi-do, South Korea). Magnolia cortex powder was dissolved in a solvent such as DPG or DMSO, and the solution was filtered through a 0.2 μm syringe filter. The filtered liquid was used as the Magnolia cortex extract.

[0154] To prepare the aloe extract of this example, aloe vera was purchased from a farm in Korea and extracted once with 70% methanol at a ratio of 1:10 at 70°C.

[0155] Example 2: Confirmation of the differentiation-promoting effects of formononetin, acetylmandelic acid, and Magnolia officinalis extract on human adipose-derived stem cells

[0156] Human adipose-derived stem cells were purchased from Lonza Inc. (Walkersville, MD, USA) and cultured according to Lonza's experimental guidelines. Differentiation into adipocytes was tested using the differentiation medium recommended by Lonza. As a positive control, rosiglitazone (1 μM) was added to the differentiation medium. To induce differentiation of adipose-derived stem cells into adipocytes, the cell culture medium was removed after 3-5 days of culture, and the cells were treated with formononetin, acetylmandelic acid, and Magnolia officinalis extract, as well as the positive control group, for 14 days.

[0157] Fourteen days after the start of differentiation into adipocytes, the cell culture medium was removed and the cells were washed with diphosphate buffered saline (DPBS) and then fixed with 10% formalin. The fixed cells were stained with Oil Red O to reveal differentiated intracellular lipids, and then observed under a microscope. The results showed that treatment with representative substances such as formononetin, acetyl mandelic acid, and Magnolia extract significantly enhanced the differentiation of adipose-derived stem cells into adipocytes compared to treatment with differentiation medium alone (negative control group) (Figure 1).

[0158] Example 3: Quantitative confirmation of the differentiation-promoting effects of 12 compounds including formononetin, Magnolia officinalis extract, and Aloe vera extract on human adipose-derived stem cells

[0159] Twelve compounds, including formononetin, Magnolia officinalis extract, and aloe extract, were treated with cultured human adipose-derived stem cells in the same manner as in Example 2 above. Oil Red O stained with 100% isopropanol was then eluted and quantified by measuring absorbance at 490 nm. The results are shown in Figure 2. The 14 compounds, including formononetin, of the present invention each showed a significant increase in the relative differentiation rate compared to the negative control group treated with differentiation medium alone, demonstrating that they promote the differentiation of adipose-derived stem cells into adipocytes and more effectively promote their differentiation into adipocytes than non-differentiating substances such as kaempferol. Therefore, the present compositions containing these compounds can be used for anti-aging purposes, such as promoting the differentiation of adipose-derived stem cells and increasing subcutaneous adipocytes, thereby increasing skin elasticity and improving wrinkles.

[0160] Example 4: Confirmation of the effect of Magnolia extract in improving lip skin wrinkles

[0161] In order to confirm the wrinkle-reducing effect of the Magnolia officinalis extract prepared in Example 1, the Magnolia officinalis extract was applied to the wrinkles on the lips and under the eyes of 12 subjects (total number of subjects).

[0162] The lip skin wrinkles were measured by taking Janus photographs, specifying a certain length of the most protruding part of the lower lip, and calculating the standard deviation of the brightness values. The range of the standard deviation of the brightness values ​​was 3 to 12, and it was confirmed that the deeper the wrinkles, the greater the standard deviation. The wrinkles under the eyes were measured by taking Janus photographs and calculating the wrinkle area using the Janus wrinkle analysis program. It was confirmed that the wrinkle values ​​ranged from 7 to 44.

[0163] Results were classified as improved when the change in lip wrinkle score was 1 or more and the change in under-eye wrinkle score was 4 or more. The criteria for the classification were based on the fact that the values ​​that clearly distinguish whether or not there is improvement with the naked eye are 2 for lip wrinkles and 8 for under-eye wrinkles, and half of these values ​​were selected as the standard for judging whether or not there is improvement.

[0164] When Magnolia extract was applied to lip skin, improvement began from the fourth week, with the number of subjects who showed improvement reaching its peak at the eighth week (8), and this was maintained until the 12th week. When Magnolia extract was applied to wrinkles under the eyes, improvement was observed at a similar rate to that of lip skin until the fourth week, and although the increase rate was lower, the number of subjects who showed improvement increased until the 12th week (Figure 3).

[0165] In addition, after applying Magnolia officinalis extract to the lips of the subjects, the wrinkle-reducing effect was maintained for up to 12 weeks, and the elasticity of the lip skin was improved (Figure 4). This confirms that Magnolia officinalis extract is effective in improving wrinkles and elasticity of the skin by promoting the differentiation of adipose stem cells and increasing the number of subcutaneous fat cells.

[0166] When comparing the wrinkle-improving effects of Magnolia extract with those of asiaticoside, a conventional wrinkle-improving ingredient, on the lips and under the eyes, it was confirmed that Magnolia extract had a faster and higher improvement rate for wrinkles on the lips than on the under the eyes, and that asiaticoside had a faster and higher improvement rate for wrinkles on the under the eyes than on the lips (Figure 5).

[0167] This shows that Magnolia extract has an effect of improving skin wrinkles, and is particularly effective in improving lip wrinkles.

[0168] Example 5: Preparation of onion, bran, bamboo, carrot and hibiscus extracts

[0169] In the present invention, the extracts of onion, rice bran, bamboo, carrot and hibiscus were extracted with methanol, and then dried to form powder for use.

[0170] Example 6: Confirmation of the proliferation-promoting effect of compounds and extracts on human-derived adipose stem cells

[0171] Human adipose-derived stem cells were purchased from Lonza (Lonza, Inc., Walkersville, MD, USA) and cultured in a carbon dioxide incubator at 37°C and 5% carbon dioxide. After treatment with each material at concentrations of 0.2 ppm, 2 ppm, and 20 ppm, the degree of cell activity of the human adipose stem cells was confirmed using a CCK-8 kit (Dojindo). The results showed that each material exhibited the highest activity at the concentrations listed in Table 1 below, with each exhibiting a high cell activity rate of more than 20% compared to the untreated group (control group) (Figure 6).

[0172] [Table 1]

[0173] Therefore, a total of 19 compounds or extracts of the present invention significantly promote the proliferation of human adipose-derived stem cells, and can be used for the purpose of anti-aging by increasing skin elasticity and improving wrinkles.

[0174] From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are merely illustrative and not limiting. The scope of the present invention should be interpreted as including within the meaning and scope of the claims below, and all modifications and variations derived from the equivalent concepts thereof, rather than the above detailed description.

Claims

1. A composition for increasing skin elasticity and improving wrinkles, containing palmitamide as an active ingredient.

2. The composition according to claim 1, wherein palmitamide promotes the differentiation of human adipose-derived stem cells into adipocytes.

3. The composition of claim 1, wherein palmitamide promotes the proliferation of human adipose-derived stem cells.

4. The composition according to claim 1, which is a cosmetic composition.

5. 10. The composition of claim 1, which is a food composition.

6. The composition of claim 1, which is a pharmaceutical composition.

7. 2. The composition according to claim 1, which is a quasi-drug composition.

8. A composition for promoting differentiation of human adipose-derived stem cells, comprising palmitamide as an active ingredient.

Images